

What is claimed is:

1. A storage stable topical emulsion composition comprising:
 - a. an internal phase that is a homogenous solution comprising:
1% to 30% by weight of urea agent,
dissolved in 10% or more by weight of a non-aqueous skin-compatible solvent selected from polyol, C₍₁₋₆₎ alkanediol, glycol ether, dimethyl ether, and a combination thereof; and
 - b. an external phase comprising 10% or more by composition weight of a silicone agent selected from cyclic, linear and branched silicones, a silicone crosspolymer, and a combination thereof,wherein the internal phase is immiscible with and contained within the external phase.
2. The composition of claim 1, wherein the external phase is a solution of the silicone agent in an oil-phase.
3. The composition of claim 1 or 2, wherein the silicone agent is selected from dimethicone, PEG-10/15 crosspolymer, dimethicone/polyethylene glycol (PEG)-10/15 crosspolymer, lauryl PEG-9 polydimethylsiloxylethyl dimethicone, and a combination thereof.
4. The composition of any one of claims 1-3, wherein the composition comprises 5 to 20% by weight of the silicone agent.
5. The composition of any one of claims 1-4, wherein the composition is storage stable (e.g., demonstrates less than 10 mol % degradation of the urea agent in the non-aqueous skin-compatible solvent) for 6 weeks at 25° C ± 2° C or 40° C ± 2° C in a sealed container.
6. The composition any one of claims 1-4, wherein the composition is storage stable (e.g., demonstrates less than 10 mol % degradation of the urea agent in the non-aqueous skin-compatible solvent) for 6 months at 25° C ± 2° C or 40° C ± 2° C in a multi-use container.
7. The composition any one of claims 1-4, wherein the composition is storage stable (e.g., demonstrates less than 10 mol % degradation of the urea agent in the non-aqueous skin-compatible solvent) for 12 months at 25° C ± 2° C or 40° C ± 2° C in a multi-use container.

8. The composition of any one of claims 1-7, wherein the urea agent is urea.
9. The composition of any one of claims 1-7, wherein the urea agent is hydroxyethyl urea.
10. The composition of any one of claims 1-7, wherein the urea agent comprises a mixture of urea and hydroxyethyl urea.
11. The composition of any one of claims 1-10, wherein the non-aqueous solvent is selected from 1,3 propanediol, 1,2 propanediol, 1,3 butanediol, 1,5 pentanediol, 1,2 hexanediol, 1,6 hexanediol, glycerol, diglycerol, ethoxydiglycol, dimethyl isosorbide and a combination thereof.
12. The composition of claim 11, wherein the solvent is 1,3 propanediol.
13. The composition of any one of claims 1-12, wherein the composition exhibits a urea degradation rate that is less than the urea degradation rate of a homogenous internal phase solution in the absence of the external phase emulsion.
14. The composition of any one of claims 1-13, wherein the composition comprises 20% to 80% by weight of the silicone agent of the external phase.
15. The composition of any one of claims 1-14, wherein the composition comprises 5% to 20% by weight of the urea agent.
16. The composition of any one of claims 1-15, wherein the percent by weight ratio of the internal phase to the external phase in the composition is 19 or less.
17. The composition of any one of claims 1-16, further comprising 10% or less by weight in total of one or more optional additional components dissolved in the first and/or external phase.
18. The composition of claim 17, wherein the one or more optional additional components are selected from tocopherols, tocotrienols (e.g., alpha, beta, delta and gamma tocopherols or alpha, beta, delta and gamma tocotrienols), ferulic acid, ascorbic acid, azelaic acid, hydroxy acids (e.g., salicylic acid), panthenol, pinus pinaster bark extract, hyaluronic acid complex, cholesterol ester, cholesterol, ceramide, linoleic acid, linolenic acid, madecassoside, acetyl

zingerone, bakuchiol, bis-ethylhexyl hydroxydimethoxy benzylmalonate, zinc oxide, and titanium dioxide

19. The composition of any one of claims 1-18, wherein the composition comprises about 5% to about 20% by weight of urea.

20. The composition of any one of claims 1-19, wherein the composition comprises about 5% by weight of urea.

21. The composition of claim 19, wherein the composition comprises about 10% by weight of urea.

22. The composition of claim 17-21, wherein the optional additional component comprises ascorbic acid.

23. The composition of claim 22, wherein the composition comprises 20% or less by weight of ascorbic acid dissolved in the internal phase or the external phase.

24. The composition of claim 23, wherein the composition comprises about 5% to 10% by weight of ascorbic acid dissolved in the internal phase or the external phase.

25. The composition of any one of claims 17-24, wherein the optional additional component comprises ferulic acid.

26. The composition of claim 25, wherein the composition comprises 0.1% to 2% by weight of ferulic acid.

27. The composition of any one of claims 17-26, wherein the optional additional component comprises vitamin E.

28. The composition of claim 27, wherein the vitamin E is selected from alpha, beta, delta and gamma tocopherols and alpha, beta, delta and gamma tocotrienols, and combinations thereof.

29. The composition of claim 27, wherein the composition comprises 2% or less by weight of vitamin E.

30. The composition of claim 17-29, wherein the optional additional component is about bis-ethylhexyl hydroxydimethoxy benzylmalonate.
31. The composition of claim 30, wherein the composition comprises 2% or less by weight of bis-ethylhexyl hydroxydimethoxy benzylmalonate.
32. The composition of any one of claims 17-31, wherein the optional additional component comprises retinol.
33. The composition of claim 32, wherein the composition comprises 1% or less by weight of retinol.
34. The composition of any one of claims 17-33, wherein the optional additional component comprises azelaic acid.
35. The composition of claim 34, wherein the composition comprises 2% to 10% by weight of azelaic acid.
36. The composition of claim 34, wherein the composition comprises 5% by weight of azelaic acid.
37. The composition of any one of claims 17-36, wherein the optional additional component comprises bakuchiol.
38. The composition of claim 37, wherein the composition comprises 2% or less of bakuchiol.
39. The composition of any one of claims 17-38, wherein the optional additional component comprises C10-C30 cholesterol/lanosterol esters.
40. The composition of claim 39, wherein the composition comprises 5% or less of C10-C30 cholesterol/lanosterol esters.
41. The composition of any one of claims 17-40, wherein the optional additional component comprises madecassoside Asiaticoside.

42. The composition of claim 41, wherein the composition comprises 1% or less by weight of madecassoside Asiaticoside.
43. The composition of claim 41, wherein the optional additional component comprises glycyrrhetic acid.
44. The composition of claim 43, wherein the composition comprises 1% or less of glycyrrhetic acid.
45. The composition of any one of claims 17-43, wherein the optional additional component comprises pinus pinaster bark extract.
46. The composition of claim 45, wherein the composition comprises 0.5% to 2% by weight of pinus pinaster bark extract.
47. The composition of any one of claims 17-46, wherein the optional additional component comprises a ceramide.
48. The composition of claim 47, wherein the ceramide is selected from ceramide EOP, ceramide AP, ceramide NG, ceramide NP, ceramide NS, ceramide EOS, ceramide S, ceramide AS, and combinations thereof.
49. The composition of claim 47, wherein the composition comprises 2% or less by weight of ceramide.
50. The composition of any one of claims 17-47, wherein the optional additional component comprises cholesterol.
51. The composition of claim 50, wherein the composition comprises less than 2% by weight of cholesterol.
52. The composition of claim 52, wherein the optional additional component comprises a free fatty acid.

53. The composition of claim 51, wherein the free fatty acid is selected from linoleic acid, linolenic acid, stearic acid, palmitic acid, oleic acid, alpha-linoleic, oleic acid, and combinations thereof.
54. The composition of claim 53, wherein the composition comprises less than 1% free fatty acid.
55. The composition of any one of claims 1-54, wherein droplets of the internal phase are contained within the external phase.
56. A ready-to-use topical preparation in a multi-use container which is pre-filled with a storage stable topical composition according to any of the claims 1-55, wherein the multi-use container comprises means for dispensing a single dose of the storage stable topical composition.
57. The preparation of claim 56, wherein the multi-use container is a time-release container that delivers urea consistently over a period of time.
58. The preparation of claim 57, wherein the time-release container does not release urea all at once.
59. The preparation of claim 56, wherein the storage stable topical composition demonstrates less than 10 mol % degradation of the urea after storage for 6 weeks at $25^{\circ}\text{C} \pm 2^{\circ}\text{C}$ or $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$ in the container.
60. The preparation of claim 56, wherein the storage stable topical composition demonstrates less than 10 mol % degradation of the urea after storage for 6 months at $25^{\circ}\text{C} \pm 2^{\circ}\text{C}$ or $40^{\circ}\text{C} \pm 2^{\circ}\text{C}$ in the container.
61. The preparation of any one of claims 56-60, wherein the storage stable topical composition is sealed in the container.
62. The preparation of any one of claims 56-62, wherein the container is placed in packaging.
63. A process for producing a storage stable emulsion composition for topical application, the process comprising:

- a) combining:
- i. 1% to 30% by weight of urea agent selected from urea, hydroxyethyl urea, and combination thereof;
 - ii. 10% to 80% by weight of a non-aqueous skin-compatible solvent selected from polyol, C₍₁₋₆₎ alkanediol, glycol ether, dimethyl ether, and a combination thereof; and
 - iii. optionally one or more additional agents;
- thereby dissolving the urea agent and one or more additional agents in the non-aqueous solvent to produce an internal phase that is a homogenous solution; and
- b) suspending in the internal phase, an external phase comprising 10% or more by weight of a silicone compound dissolved in an oil-phase solution; to produce an emulsion composition that is storage stable.

64. The process of claim 61, wherein the silicone compound is selected from cyclic, linear and branched silicones, a silicone crosspolymer, and a combination thereof.

65. The process of claim 61 or 62, wherein the one or more additional agents comprise ascorbic acid.

66. The process of claim 61, wherein the internal phase comprises 20% or less by weight of ascorbic acid.

67. The process of claim 64, wherein the internal phase comprises about 5% to about 10% by weight of ascorbic acid.

68. The process of any one of claims 61-65, wherein the one or more additional agents comprise ferulic acid.

69. The process of claim 66, wherein the composition comprises 2% or less by weight of ferulic acid.

70. The process of claim 61, wherein the one or more additional agents comprise:
0.5% to 2% ferulic acid; and
0.5% to 2% pinus pinaster bark extract.

71. The process of claim 61, wherein the one or more additional agents comprise about 3% to about 10% by weight azelaic acid.
72. The process of any one of claims 61-69, wherein the external phase further comprises a lipid component.
73. The process of claim 70, wherein the lipid component is selected from cholesterol, ceramides, free fatty acids, and combinations thereof.
74. The process of any one of claims 61-71, wherein the external phase prevents or reduces precipitation of urea out of the emulsion composition.
75. The process of any one of claims 61-72, wherein the urea agent, prior to dissolving in the non-aqueous solvent, is a crystalline form of the urea agent with a particle size of about 100 μm or more.
76. The process of claim 70, wherein suspending the internal phase in the external phase prevents or reduces recrystallization of urea from the internal phase.
77. The process of claim 74, wherein said suspending comprises suspending droplets of the internal phase within the external phase.
78. A product produced by the process according to any one of claims 61-77.
79. The product of claim 78, wherein the product is a serum.